Quinolone derivative or pharmaceutically acceptable salt thereof

To provide a pharmaceutical agent having a P2Y12 inhibitory activity, particularly a compound useful as a platelet aggregation inhibitor. An extensive study was made on an P2Y12 inhibitor, and it was found that a quinolone derivative having a substituted carbamoyl group at position-3 wherein the sub...

Full description

Saved in:
Bibliographic Details
Main Authors KAMIKUBO, TAKASHI, KOGA, YUJI, OKUDA, TAKAO, MORITOMO, HIROYUKI, KAGEYAMA, MICHIHITO
Format Patent
LanguageChinese
English
Published 16.07.2008
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:To provide a pharmaceutical agent having a P2Y12 inhibitory activity, particularly a compound useful as a platelet aggregation inhibitor. An extensive study was made on an P2Y12 inhibitor, and it was found that a quinolone derivative having a substituted carbamoyl group at position-3 wherein the substituent on the carbamoyl group is -(polymethylene in which a carbon atom adjacent to the carbamoyl group is substituted)-CO2R (wherein R represents -H or a lower alkyl) has an excellent platelet aggregation inhibitory activity and has improved in vivo kinetics. The compound is excellent in P2Y12 inhibitory activity and platelet aggregation inhibitory activity, and is therefore useful as a platelet aggregation inhibitor.
Bibliography:Application Number: TW200796143052